title: Periprocedural management of antithrombotic therapy in hospitalized patients.
abstract: The management of antithrombotic medications in patients requiring invasive procedures is a common problem in hospital medicine, for which there is limited evidence to guide clinical decision making. Existing guidelines do not address many hospital-based procedures and have not kept pace with the introduction of newer antiplatelet and anticoagulant medications. This article provides a conceptual framework for the periprocedural management of antithrombotic therapy, with a focus on the procedures that hospitalists are most likely to perform and the pharmacology of the common and newer antithrombotic medications.
authors.affiliation: Section of Hospital Medicine, Division of General Medicine and Primary Care, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
authors.forename: David
authors.initials: D
authors.lastname: Feinbloom
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects / Q000592:standards; D002983:Clinical Competence / Q000592:standards*; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000592:standards; D017408:Guidelines as Topic; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D019990:Perioperative Care / Q000379:methods / Q000592:standards*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000592:standards; D018570:Risk Assessment; D013927:Thrombosis / Q000188:drug therapy / Q000517:prevention & control*; D013997:Time Factors
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors